Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics

Drug Profile

Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics

Alternative Names: Aloradine IN; Aloradine NS; AM-005; PH-94B; PH94B NS

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Pherin Pharmaceuticals; VistaGen Therapeutics
  • Class Anxiolytics; Behavioural disorder therapies; Small molecules; Steroids
  • Mechanism of Action Chemoreceptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Social phobia
  • Phase II Adjustment disorders

Most Recent Events

  • 13 Feb 2024 VistaGen Therapeutics plans a phase III PALISADE-3 trial in Social phobia (Intranasal, Spray) in USA in 1H of 2024
  • 13 Feb 2024 VistaGen Therapeutics plans a phase III PALISADE-4 trial in Social phobia (In adults) in USA (Intranasal, Spray) in the second half of 2024
  • 09 Nov 2023 VistaGen Therapeutics intends to file a New Drug Application (NDA) to the US FDA for Social phobia (In adults) in the first half of 2026
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top